Drug− drug interactions (DDIs) occur when a patient's response to the drug is modified by
administration or co‐exposure to another drug. The main cytochrome P 450 (CYP) enzyme …

The extensive use of tyrosine kinase inhibitors (TKI's) in hematology and oncology has
shown that these drugs have a significant potential for drug‐drug interactions. Since these …

Background Sunitinib and pazopanib are both oral small molecule multityrosine kinase
inhibitors (MTKI) used in the treatment of renal cell carcinoma (RCC). Hepatotoxicity or “liver …

Purpose Sunitinib is a tyrosine kinase inhibitor indicated for the treatment of gastrointestinal
stromal tumor, advanced renal cell carcinoma, and pancreatic neuroendocrine tumors. The …

Background Diabetes is one of the most common metabolic diseases in the world, which
may influence changes in the pharmacokinetics and pharmacodynamics of drugs. Sunitinib …

Background Tegoprazan is a potassium-competitive acid blocker that inhibits gastric acid
and which may be used for eradicating Helicobacter pylori. This study focuses on the …

Background Fluoroquinolones are widely prescribed antibiotics. Ciprofloxacin is a well-
known inhibitor of cytochrome P450 CYP3A4 and causes numerous drug interactions that …

Обсуждается роль бактериальной инфекции в патогенезе хронического бронхита,
ХОБЛ и пневмоний. Излагаются подходы к диагностике пневмоний и показания к …

The number of people diagnosed with cancer during their lifetime has been steadily
increasing.[1] This increase in prevalence across the survivorship trajectory is attributed to …

Tyrosine kinase inhibitors (TKIs) are applied in targeted therapy, which is based on the effect
of drugs on malfunctioning neoplastic cells. Tyrosine kinases are responsible for transmitting …